line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,-68417508.417508,TORNTPHARM.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.285073,TORNTPHARM.NS
Normalized EBITDA,2025-03-31 00:00:00,37440000000.0,TORNTPHARM.NS
Total Unusual Items,2025-03-31 00:00:00,-240000000.0,TORNTPHARM.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,-240000000.0,TORNTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,19110000000.0,TORNTPHARM.NS
Reconciled Depreciation,2025-03-31 00:00:00,7950000000.0,TORNTPHARM.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,27760000000.0,TORNTPHARM.NS
EBITDA,2025-03-31 00:00:00,37200000000.0,TORNTPHARM.NS
EBIT,2025-03-31 00:00:00,29250000000.0,TORNTPHARM.NS
Net Interest Income,2025-03-31 00:00:00,-2520000000.0,TORNTPHARM.NS
Interest Expense,2025-03-31 00:00:00,2520000000.0,TORNTPHARM.NS
Interest Income,2025-03-31 00:00:00,,TORNTPHARM.NS
Normalized Income,2025-03-31 00:00:00,19281582491.582493,TORNTPHARM.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,19110000000.0,TORNTPHARM.NS
Total Expenses,2025-03-31 00:00:00,83910000000.0,TORNTPHARM.NS
Diluted Average Shares,2025-03-31 00:00:00,338409775.0,TORNTPHARM.NS
Basic Average Shares,2025-03-31 00:00:00,338409775.0,TORNTPHARM.NS
Diluted EPS,2025-03-31 00:00:00,56.47,TORNTPHARM.NS
Basic EPS,2025-03-31 00:00:00,56.47,TORNTPHARM.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,19110000000.0,TORNTPHARM.NS
Net Income Common Stockholders,2025-03-31 00:00:00,19110000000.0,TORNTPHARM.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,TORNTPHARM.NS
Net Income,2025-03-31 00:00:00,19110000000.0,TORNTPHARM.NS
Minority Interests,2025-03-31 00:00:00,0.0,TORNTPHARM.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,19110000000.0,TORNTPHARM.NS
Net Income Continuous Operations,2025-03-31 00:00:00,19110000000.0,TORNTPHARM.NS
Tax Provision,2025-03-31 00:00:00,7620000000.0,TORNTPHARM.NS
Pretax Income,2025-03-31 00:00:00,26730000000.0,TORNTPHARM.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,230000000.0,TORNTPHARM.NS
Special Income Charges,2025-03-31 00:00:00,-240000000.0,TORNTPHARM.NS
Other Special Charges,2025-03-31 00:00:00,,TORNTPHARM.NS
Impairment Of Capital Assets,2025-03-31 00:00:00,,TORNTPHARM.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-2520000000.0,TORNTPHARM.NS
Total Other Finance Cost,2025-03-31 00:00:00,,TORNTPHARM.NS
Interest Expense Non Operating,2025-03-31 00:00:00,2520000000.0,TORNTPHARM.NS
Interest Income Non Operating,2025-03-31 00:00:00,,TORNTPHARM.NS
Operating Income,2025-03-31 00:00:00,29260000000.0,TORNTPHARM.NS
Operating Expense,2025-03-31 00:00:00,56150000000.0,TORNTPHARM.NS
Other Operating Expenses,2025-03-31 00:00:00,28160000000.0,TORNTPHARM.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,7950000000.0,TORNTPHARM.NS
Amortization,2025-03-31 00:00:00,,TORNTPHARM.NS
Depreciation Income Statement,2025-03-31 00:00:00,7950000000.0,TORNTPHARM.NS
Research And Development,2025-03-31 00:00:00,,TORNTPHARM.NS
Selling General And Administration,2025-03-31 00:00:00,,TORNTPHARM.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,TORNTPHARM.NS
General And Administrative Expense,2025-03-31 00:00:00,,TORNTPHARM.NS
Gross Profit,2025-03-31 00:00:00,85410000000.0,TORNTPHARM.NS
Cost Of Revenue,2025-03-31 00:00:00,27760000000.0,TORNTPHARM.NS
Total Revenue,2025-03-31 00:00:00,113170000000.0,TORNTPHARM.NS
Operating Revenue,2025-03-31 00:00:00,113170000000.0,TORNTPHARM.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,260408163.265306,TORNTPHARM.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.295918,TORNTPHARM.NS
Normalized EBITDA,2024-03-31 00:00:00,34260000000.0,TORNTPHARM.NS
Total Unusual Items,2024-03-31 00:00:00,880000000.0,TORNTPHARM.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,880000000.0,TORNTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,16560000000.0,TORNTPHARM.NS
Reconciled Depreciation,2024-03-31 00:00:00,8080000000.0,TORNTPHARM.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,26860000000.0,TORNTPHARM.NS
EBITDA,2024-03-31 00:00:00,35140000000.0,TORNTPHARM.NS
EBIT,2024-03-31 00:00:00,27060000000.0,TORNTPHARM.NS
Net Interest Income,2024-03-31 00:00:00,-3540000000.0,TORNTPHARM.NS
Interest Expense,2024-03-31 00:00:00,3540000000.0,TORNTPHARM.NS
Interest Income,2024-03-31 00:00:00,114800000.0,TORNTPHARM.NS
Normalized Income,2024-03-31 00:00:00,15940408163.265306,TORNTPHARM.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,16560000000.0,TORNTPHARM.NS
Total Expenses,2024-03-31 00:00:00,80020000000.0,TORNTPHARM.NS
Diluted Average Shares,2024-03-31 00:00:00,338373519.0,TORNTPHARM.NS
Basic Average Shares,2024-03-31 00:00:00,338373519.0,TORNTPHARM.NS
Diluted EPS,2024-03-31 00:00:00,48.94,TORNTPHARM.NS
Basic EPS,2024-03-31 00:00:00,48.94,TORNTPHARM.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,16560000000.0,TORNTPHARM.NS
Net Income Common Stockholders,2024-03-31 00:00:00,16560000000.0,TORNTPHARM.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,TORNTPHARM.NS
Net Income,2024-03-31 00:00:00,16560000000.0,TORNTPHARM.NS
Minority Interests,2024-03-31 00:00:00,0.0,TORNTPHARM.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,16560000000.0,TORNTPHARM.NS
Net Income Continuous Operations,2024-03-31 00:00:00,16560000000.0,TORNTPHARM.NS
Tax Provision,2024-03-31 00:00:00,6960000000.0,TORNTPHARM.NS
Pretax Income,2024-03-31 00:00:00,23520000000.0,TORNTPHARM.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,580000000.0,TORNTPHARM.NS
Special Income Charges,2024-03-31 00:00:00,880000000.0,TORNTPHARM.NS
Other Special Charges,2024-03-31 00:00:00,-880000000.0,TORNTPHARM.NS
Impairment Of Capital Assets,2024-03-31 00:00:00,129700000.0,TORNTPHARM.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-3540000000.0,TORNTPHARM.NS
Total Other Finance Cost,2024-03-31 00:00:00,9300000.0,TORNTPHARM.NS
Interest Expense Non Operating,2024-03-31 00:00:00,3540000000.0,TORNTPHARM.NS
Interest Income Non Operating,2024-03-31 00:00:00,114800000.0,TORNTPHARM.NS
Operating Income,2024-03-31 00:00:00,25600000000.0,TORNTPHARM.NS
Operating Expense,2024-03-31 00:00:00,53160000000.0,TORNTPHARM.NS
Other Operating Expenses,2024-03-31 00:00:00,26900000000.0,TORNTPHARM.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,8080000000.0,TORNTPHARM.NS
Amortization,2024-03-31 00:00:00,5429200000.0,TORNTPHARM.NS
Depreciation Income Statement,2024-03-31 00:00:00,8080000000.0,TORNTPHARM.NS
Research And Development,2024-03-31 00:00:00,247300000.0,TORNTPHARM.NS
Selling General And Administration,2024-03-31 00:00:00,19019600000.0,TORNTPHARM.NS
Selling And Marketing Expense,2024-03-31 00:00:00,11296800000.0,TORNTPHARM.NS
General And Administrative Expense,2024-03-31 00:00:00,7722800000.0,TORNTPHARM.NS
Gross Profit,2024-03-31 00:00:00,78760000000.0,TORNTPHARM.NS
Cost Of Revenue,2024-03-31 00:00:00,26860000000.0,TORNTPHARM.NS
Total Revenue,2024-03-31 00:00:00,105620000000.0,TORNTPHARM.NS
Operating Revenue,2024-03-31 00:00:00,105620000000.0,TORNTPHARM.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,119181630.0,TORNTPHARM.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.3259,TORNTPHARM.NS
Normalized EBITDA,2023-03-31 00:00:00,28448600000.0,TORNTPHARM.NS
Total Unusual Items,2023-03-31 00:00:00,365700000.0,TORNTPHARM.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,365700000.0,TORNTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,12452300000.0,TORNTPHARM.NS
Reconciled Depreciation,2023-03-31 00:00:00,7020300000.0,TORNTPHARM.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,28276900000.0,TORNTPHARM.NS
EBITDA,2023-03-31 00:00:00,28814300000.0,TORNTPHARM.NS
EBIT,2023-03-31 00:00:00,21794000000.0,TORNTPHARM.NS
Net Interest Income,2023-03-31 00:00:00,-3186600000.0,TORNTPHARM.NS
Interest Expense,2023-03-31 00:00:00,3322400000.0,TORNTPHARM.NS
Interest Income,2023-03-31 00:00:00,147800000.0,TORNTPHARM.NS
Normalized Income,2023-03-31 00:00:00,12205781630.0,TORNTPHARM.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,12452300000.0,TORNTPHARM.NS
Total Expenses,2023-03-31 00:00:00,73236700000.0,TORNTPHARM.NS
Diluted Average Shares,2023-03-31 00:00:00,338445440.0,TORNTPHARM.NS
Basic Average Shares,2023-03-31 00:00:00,338445440.0,TORNTPHARM.NS
Diluted EPS,2023-03-31 00:00:00,36.79,TORNTPHARM.NS
Basic EPS,2023-03-31 00:00:00,36.79,TORNTPHARM.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,12452300000.0,TORNTPHARM.NS
Net Income Common Stockholders,2023-03-31 00:00:00,12452300000.0,TORNTPHARM.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,TORNTPHARM.NS
Net Income,2023-03-31 00:00:00,12452300000.0,TORNTPHARM.NS
Minority Interests,2023-03-31 00:00:00,0.0,TORNTPHARM.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,12452300000.0,TORNTPHARM.NS
Net Income Continuous Operations,2023-03-31 00:00:00,12452300000.0,TORNTPHARM.NS
Tax Provision,2023-03-31 00:00:00,6019300000.0,TORNTPHARM.NS
Pretax Income,2023-03-31 00:00:00,18471600000.0,TORNTPHARM.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,73100000.0,TORNTPHARM.NS
Special Income Charges,2023-03-31 00:00:00,170600000.0,TORNTPHARM.NS
Other Special Charges,2023-03-31 00:00:00,-216200000.0,TORNTPHARM.NS
Impairment Of Capital Assets,2023-03-31 00:00:00,45600000.0,TORNTPHARM.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-3186600000.0,TORNTPHARM.NS
Total Other Finance Cost,2023-03-31 00:00:00,12000000.0,TORNTPHARM.NS
Interest Expense Non Operating,2023-03-31 00:00:00,3322400000.0,TORNTPHARM.NS
Interest Income Non Operating,2023-03-31 00:00:00,147800000.0,TORNTPHARM.NS
Operating Income,2023-03-31 00:00:00,21400200000.0,TORNTPHARM.NS
Operating Expense,2023-03-31 00:00:00,44959800000.0,TORNTPHARM.NS
Other Operating Expenses,2023-03-31 00:00:00,5133100000.0,TORNTPHARM.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,7020300000.0,TORNTPHARM.NS
Amortization,2023-03-31 00:00:00,4765600000.0,TORNTPHARM.NS
Depreciation Income Statement,2023-03-31 00:00:00,2254700000.0,TORNTPHARM.NS
Research And Development,2023-03-31 00:00:00,312700000.0,TORNTPHARM.NS
Selling General And Administration,2023-03-31 00:00:00,16407500000.0,TORNTPHARM.NS
Selling And Marketing Expense,2023-03-31 00:00:00,10269900000.0,TORNTPHARM.NS
General And Administrative Expense,2023-03-31 00:00:00,6137600000.0,TORNTPHARM.NS
Gross Profit,2023-03-31 00:00:00,66360000000.0,TORNTPHARM.NS
Cost Of Revenue,2023-03-31 00:00:00,28276900000.0,TORNTPHARM.NS
Total Revenue,2023-03-31 00:00:00,94636900000.0,TORNTPHARM.NS
Operating Revenue,2023-03-31 00:00:00,94636900000.0,TORNTPHARM.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,-1737731400.0,TORNTPHARM.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.366,TORNTPHARM.NS
Normalized EBITDA,2022-03-31 00:00:00,26155600000.0,TORNTPHARM.NS
Total Unusual Items,2022-03-31 00:00:00,-4747900000.0,TORNTPHARM.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,-4747900000.0,TORNTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,7771800000.0,TORNTPHARM.NS
Reconciled Depreciation,2022-03-31 00:00:00,6619300000.0,TORNTPHARM.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,25374700000.0,TORNTPHARM.NS
EBITDA,2022-03-31 00:00:00,21407700000.0,TORNTPHARM.NS
EBIT,2022-03-31 00:00:00,14788400000.0,TORNTPHARM.NS
Net Interest Income,2022-03-31 00:00:00,-2479100000.0,TORNTPHARM.NS
Interest Expense,2022-03-31 00:00:00,2529300000.0,TORNTPHARM.NS
Interest Income,2022-03-31 00:00:00,71500000.0,TORNTPHARM.NS
Normalized Income,2022-03-31 00:00:00,10781968600.0,TORNTPHARM.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,7771800000.0,TORNTPHARM.NS
Total Expenses,2022-03-31 00:00:00,66494600000.0,TORNTPHARM.NS
Diluted Average Shares,2022-03-31 00:00:00,338445440.0,TORNTPHARM.NS
Basic Average Shares,2022-03-31 00:00:00,338445440.0,TORNTPHARM.NS
Diluted EPS,2022-03-31 00:00:00,22.96,TORNTPHARM.NS
Basic EPS,2022-03-31 00:00:00,22.96,TORNTPHARM.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,7771800000.0,TORNTPHARM.NS
Net Income Common Stockholders,2022-03-31 00:00:00,7771800000.0,TORNTPHARM.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,TORNTPHARM.NS
Net Income,2022-03-31 00:00:00,7771800000.0,TORNTPHARM.NS
Minority Interests,2022-03-31 00:00:00,0.0,TORNTPHARM.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,7771800000.0,TORNTPHARM.NS
Net Income Continuous Operations,2022-03-31 00:00:00,7771800000.0,TORNTPHARM.NS
Tax Provision,2022-03-31 00:00:00,4487300000.0,TORNTPHARM.NS
Pretax Income,2022-03-31 00:00:00,12259100000.0,TORNTPHARM.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,97300000.0,TORNTPHARM.NS
Special Income Charges,2022-03-31 00:00:00,-4849300000.0,TORNTPHARM.NS
Other Special Charges,2022-03-31 00:00:00,456800000.0,TORNTPHARM.NS
Impairment Of Capital Assets,2022-03-31 00:00:00,4392500000.0,TORNTPHARM.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-2479100000.0,TORNTPHARM.NS
Total Other Finance Cost,2022-03-31 00:00:00,21300000.0,TORNTPHARM.NS
Interest Expense Non Operating,2022-03-31 00:00:00,2529300000.0,TORNTPHARM.NS
Interest Income Non Operating,2022-03-31 00:00:00,71500000.0,TORNTPHARM.NS
Operating Income,2022-03-31 00:00:00,17693400000.0,TORNTPHARM.NS
Operating Expense,2022-03-31 00:00:00,41119900000.0,TORNTPHARM.NS
Other Operating Expenses,2022-03-31 00:00:00,4449200000.0,TORNTPHARM.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,6619300000.0,TORNTPHARM.NS
Amortization,2022-03-31 00:00:00,4157000000.0,TORNTPHARM.NS
Depreciation Income Statement,2022-03-31 00:00:00,2462300000.0,TORNTPHARM.NS
Research And Development,2022-03-31 00:00:00,386500000.0,TORNTPHARM.NS
Selling General And Administration,2022-03-31 00:00:00,14397900000.0,TORNTPHARM.NS
Selling And Marketing Expense,2022-03-31 00:00:00,8849100000.0,TORNTPHARM.NS
General And Administrative Expense,2022-03-31 00:00:00,5548800000.0,TORNTPHARM.NS
Gross Profit,2022-03-31 00:00:00,58813300000.0,TORNTPHARM.NS
Cost Of Revenue,2022-03-31 00:00:00,25374700000.0,TORNTPHARM.NS
Total Revenue,2022-03-31 00:00:00,84188000000.0,TORNTPHARM.NS
Operating Revenue,2022-03-31 00:00:00,84188000000.0,TORNTPHARM.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,TORNTPHARM.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,TORNTPHARM.NS
Normalized EBITDA,2021-03-31 00:00:00,,TORNTPHARM.NS
Total Unusual Items,2021-03-31 00:00:00,,TORNTPHARM.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,TORNTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,TORNTPHARM.NS
Reconciled Depreciation,2021-03-31 00:00:00,,TORNTPHARM.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,TORNTPHARM.NS
EBITDA,2021-03-31 00:00:00,,TORNTPHARM.NS
EBIT,2021-03-31 00:00:00,,TORNTPHARM.NS
Net Interest Income,2021-03-31 00:00:00,,TORNTPHARM.NS
Interest Expense,2021-03-31 00:00:00,,TORNTPHARM.NS
Interest Income,2021-03-31 00:00:00,50700000.0,TORNTPHARM.NS
Normalized Income,2021-03-31 00:00:00,,TORNTPHARM.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,TORNTPHARM.NS
Total Expenses,2021-03-31 00:00:00,,TORNTPHARM.NS
Diluted Average Shares,2021-03-31 00:00:00,,TORNTPHARM.NS
Basic Average Shares,2021-03-31 00:00:00,,TORNTPHARM.NS
Diluted EPS,2021-03-31 00:00:00,,TORNTPHARM.NS
Basic EPS,2021-03-31 00:00:00,,TORNTPHARM.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,TORNTPHARM.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,TORNTPHARM.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,TORNTPHARM.NS
Net Income,2021-03-31 00:00:00,,TORNTPHARM.NS
Minority Interests,2021-03-31 00:00:00,,TORNTPHARM.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,TORNTPHARM.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,TORNTPHARM.NS
Tax Provision,2021-03-31 00:00:00,,TORNTPHARM.NS
Pretax Income,2021-03-31 00:00:00,,TORNTPHARM.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,TORNTPHARM.NS
Special Income Charges,2021-03-31 00:00:00,,TORNTPHARM.NS
Other Special Charges,2021-03-31 00:00:00,,TORNTPHARM.NS
Impairment Of Capital Assets,2021-03-31 00:00:00,4800000.0,TORNTPHARM.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,TORNTPHARM.NS
Total Other Finance Cost,2021-03-31 00:00:00,21200000.0,TORNTPHARM.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,TORNTPHARM.NS
Interest Income Non Operating,2021-03-31 00:00:00,50700000.0,TORNTPHARM.NS
Operating Income,2021-03-31 00:00:00,,TORNTPHARM.NS
Operating Expense,2021-03-31 00:00:00,,TORNTPHARM.NS
Other Operating Expenses,2021-03-31 00:00:00,,TORNTPHARM.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,TORNTPHARM.NS
Amortization,2021-03-31 00:00:00,4206000000.0,TORNTPHARM.NS
Depreciation Income Statement,2021-03-31 00:00:00,,TORNTPHARM.NS
Research And Development,2021-03-31 00:00:00,251800000.0,TORNTPHARM.NS
Selling General And Administration,2021-03-31 00:00:00,13082900000.0,TORNTPHARM.NS
Selling And Marketing Expense,2021-03-31 00:00:00,7426300000.0,TORNTPHARM.NS
General And Administrative Expense,2021-03-31 00:00:00,5656600000.0,TORNTPHARM.NS
Gross Profit,2021-03-31 00:00:00,,TORNTPHARM.NS
Cost Of Revenue,2021-03-31 00:00:00,,TORNTPHARM.NS
Total Revenue,2021-03-31 00:00:00,,TORNTPHARM.NS
Operating Revenue,2021-03-31 00:00:00,,TORNTPHARM.NS
